Financial Performance - In Q1 2024, the company achieved a revenue of 10.774 billion CNY, a year-on-year increase of 2.49% [2] - The net profit attributable to shareholders was 1.702 billion CNY, up 12.12% year-on-year [2] - The net profit after deducting non-recurring gains and losses reached 1.690 billion CNY, growing by 20.51% [2] - Basic earnings per share were 0.95 CNY, reflecting an 11.76% increase [2] - The weighted average return on equity was 4.18%, an increase of 0.31 percentage points year-on-year [2] Market Position and Online Strategy - In 2023, the health product segment generated a revenue of 6.422 billion CNY, with a year-on-year growth of 6.50% [3] - Yunnan Baiyao toothpaste held a 24.60% market share in the domestic market, maintaining the leading position [3] - During the "Double 11" shopping festival, the health product segment achieved multiple top rankings, with the Yunnan Baiyao Tmall flagship store surpassing 100 million CNY in sales for the first time [3][4] - The company actively engaged in online promotions during major shopping events and collaborated with e-commerce platforms to enhance brand visibility [4] Development Plans for Traditional Chinese Medicine Resources - The Traditional Chinese Medicine Resources Division aims to leverage Yunnan's rich medicinal material resources, focusing on user demand and sustainable supply chain development [5] - The brand medicinal materials segment will expand by enhancing the three-seven industry platform and developing other advantageous medicinal materials [5] - The natural plant extraction segment will refine operations and innovate production techniques to capture market share [5] Overall Business Strategy for 2024 - The company will focus on strategic leadership, emphasizing growth and efficiency in its core pharmaceutical, health, and traditional Chinese medicine resources [7] - The strategy includes optimizing product and industry structures to create new growth points while enhancing internal operational efficiency [7] - The goal is to achieve sustainable growth through a coordinated development of scale, structure, and quality [7]
云南白药(000538) - 2024年6月14日调研活动附件之投资者调研会议记录(二)